At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
Displaying 271–280 of 566 results.
-
Myelofibrosis is a rare disease known as a myeloproliferative neoplasm. The bone marrow becomes scarred and cannot make enough blood cells, leading to anemia. Anemia is low number of red blood cells, causing tiredness and shortness of breath. Some people with myelofibrosis need regular transfusions of blood. In this study, researchers want to see if momelotinib given with luspatercept reduces the need for blood transfusions in these patients. Momelotinib works by blocking two proteins called JAK and ACVR1. When JAK proteins send too many signals, the body makes the wrong amount of blood cells. By blocking JAK, momelotinib may help your body make the right amount of blood cells. By targeting ACVR1, momelotinib may fight anemia. Momelotinib is taken orally (by mouth).  By improving red blood cell development, luspatercept may reduce the need for blood transfusions in people with transfusion-dependent myelofibrosis. Luspatercept is given by an injection under the skin. 
-
Researchers are doing this study to learn if lung chemoembolization is safe and works well in people with lung cancer. The people in this study have non-small cell lung cancer that keeps growing after chemotherapy. Moreover, it cannot be cured with surgery or radiation therapy.
-
I-DXd is a type of drug called an antibody-drug conjugate (ADC). ADCs are made of a monoclonal antibody linked to a drug. The antibody binds to a protein on cancer cells called B7-H3, which plays a role in cancer cell growth. It then releases the anti-cancer drug to kill the cancer cell. By destroying these cells, I-DXd may help slow or stop the growth of your cancer.
-
Casdozokitug blocks an immune system protein called IL-27. By binding to and blocking IL-27, casdozokitug may help immune cells fight cancer. Toripalimab also helps the immune system fight cancer. Bevacizumab prevents the growth of new blood vessels that feed the cancer. All three drugs are given intravenously (by vein).
-
Researchers are comparing RMC-6236 with docetaxel for the treatment of lung cancer. The people in this study have non-small cell lung cancer (NSCLC) that has spread beyond its original location. In addition, their tumors have a mutation (change) in the RAS gene.
-
The purpose of this study is to assess the safety and effectiveness of treating rare advanced genitourinary cancers with the immunotherapies nivolumab and ipilimumab plus the drug cabozantinib.
-
The purpose of this study is to compare the safety and effectiveness of personalized drug treatments that are given before surgery to remove stage I, II, or III non-small cell lung cancer (NSCLC) in patients whose tumors have certain genetic changes (mutations). Researchers believe these targeted therapies may effectively treat the tumor before surgery.
-
Researchers are assessing two different doses of revumenib to give with azacitidine and venetoclax in young people with leukemia. This study includes children, teens, and young adults with acute myeloid leukemia (AML) or acute leukemia of ambiguous lineage (ALAL) that came back or keeps progressing after treatment.
-
Researchers want to find the best dose of INCB161734 to use in people with advanced cancer. The people in this study have solid tumors that have spread. In addition, their cancers have a genetic mutation (change) called KRAS G12D.
-
Researchers are comparing RMC-6236 with standard therapy in people with advanced pancreatic cancer. The people in this study have pancreatic cancer that has metastasized (spread) and keeps growing even after treatment.